Clinical Microbiology Reviews最新文献_第2页

A call for the United States to continue investing in science. 呼吁美国继续对科学进行投资。

IF 19 1区医学

Clinical Microbiology Reviews Pub Date : 2025-06-12 Epub Date: 2025-02-27 DOI: 10.1128/cmr.00044-25

Ira Blader, Felicia Goodrum, Michael J Imperiale, Arturo Casadevall, Cesar A Arias, Andreas Baumler, Carey-Ann D Burnham, Christina A Cuomo, Corrella S Detweiler, Graeme N Forrest, Jack A Gilbert, Susan Lovett, Stanley Maloy, Alexander McAdam, Irene Newton, Gemma Reguera, George A O'Toole, Patrick D Schloss, Ashley Shade, Marvin Whiteley

引用次数: 0

Erratum for Kramer et al., 'How long do bacteria, fungi, protozoa, and viruses retain their replication capacity on inanimate surfaces? A systematic review examining environmental resilience versus healthcare-associated infection risk by "fomite-borne risk assessment"'. 对Kramer等人的勘误，“细菌、真菌、原生动物和病毒在无生命表面上的复制能力能保持多久？”通过“污染物传播风险评估”对环境恢复力与卫生保健相关感染风险进行系统审查。

IF 19 1区医学

Clinical Microbiology Reviews Pub Date : 2025-06-04 DOI: 10.1128/cmr.00129-25

Axel Kramer, Franziska Lexow, Anna Bludau, Antonia Milena Köster, Martin Misailovski, Ulrike Seifert, Maren Eggers, William Rutala, Stephanie J Dancer, Simone Scheithauer

引用次数: 0

Skin microbiota in atopic dermatitis: victim or executioner? 特应性皮炎的皮肤微生物群：受害者还是刽子手？

IF 19 1区医学

Clinical Microbiology Reviews Pub Date : 2025-06-03 DOI: 10.1128/cmr.00277-24

Chiara Maria Teresa Boggio, Federica Veronese, Marta Armari, Elisa Zavattaro, Elia Esposto, Paola Savoia, Barbara Azzimonti

{"title":"Skin microbiota in atopic dermatitis: victim or executioner?","authors":"Chiara Maria Teresa Boggio, Federica Veronese, Marta Armari, Elisa Zavattaro, Elia Esposto, Paola Savoia, Barbara Azzimonti","doi":"10.1128/cmr.00277-24","DOIUrl":"https://doi.org/10.1128/cmr.00277-24","url":null,"abstract":"SUMMARYAtopic dermatitis (AD) is a prevalent chronic inflammatory skin disorder, affecting 10%-20% of the population, characterized by dryness, intense itching, and recurrent rashes. The pathophysiology of AD is multifactorial, involving skin barrier dysfunction, immune dysregulation, genetic factors (such as filaggrin mutations), and environmental factors. The skin microbiota also plays a pivotal role in AD, serving both as a target and a driver of the disease. In AD, the delicate balance of the skin microbiota is disrupted, leading to a decrease in beneficial bacteria such as Streptococcus, Cutibacterium, and Corynebacterium. Concurrently, bacterial pathobionts, notably Staphylococcus aureus, proliferate and express their virulence factors excessively. This imbalance exacerbates symptoms by damaging the skin barrier, releasing toxins, and triggering a Th2-driven immune response, thus weakening the skin defenses and making individuals with AD more susceptible to bacterial, fungal, and viral infections, thereby complicating treatment and worsening disease outcomes. Effective AD management requires a thorough understanding of the interplay among the skin microbiota, the immune system, and microbial pathobionts. Strategies that restore the microbial balance, preserve the skin barrier, and modulate the immune response show significant potential for reducing infections and improving AD symptoms, highlighting the microbiota's dual role in AD pathology. This review examines the complex role of the skin microbiota in AD, emphasizing how dysbiosis both drives disease progression and influences immune responses, and vice versa. It also explores emerging microbiota-targeted therapies aimed at improving disease outcomes.","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":" ","pages":"e0027724"},"PeriodicalIF":19.0,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biologic drug development for treatment and prevention of sexually transmitted infections. 用于治疗和预防性传播感染的生物药物开发。

IF 19 1区医学

Clinical Microbiology Reviews Pub Date : 2025-05-29 DOI: 10.1128/cmr.00107-24

Davinder S Gill, Sanjay Ram, Peter A Rice

{"title":"Biologic drug development for treatment and prevention of sexually transmitted infections.","authors":"Davinder S Gill, Sanjay Ram, Peter A Rice","doi":"10.1128/cmr.00107-24","DOIUrl":"https://doi.org/10.1128/cmr.00107-24","url":null,"abstract":"SUMMARYSexually transmitted infections (STIs) represent a significant global health burden, with over one million new infections occurring daily. In some instances, the prevalence of antibiotic-resistant pathogens is rising, which exacerbates the challenge. STIs cause severe complications, including infertility, ectopic pregnancies, pre-term births, and heightened risks of HIV acquisition. These outcomes underscore the need for innovative therapeutic and prophylactic strategies. In this review, we provide a comprehensive analysis of the current state of biologic drug development targeting key STIs, focusing on Chlamydia trachomatis, Neisseria gonorrhoeae, herpes simplex virus type 2 (HSV-2), and Treponema pallidum. We examine the complexity of host-pathogen interactions that inform biologic drug design, such as multiple mechanisms of infection, immune evasion strategies, and pathogenic latency. We also explore the role of mucosal immunity, highlighting advances in resident memory T cells and cytokine-driven responses that guide therapeutic targeting, concentrating on Chlamydia trachomatis and Neisseria gonorrhoeae, where recent advances in vaccine development appear promising. We conduct a comprehensive survey of platforms, including vaccines, and explore modalities such as monoclonal antibodies and protein therapeutics. Additionally, we examine emerging technologies like nucleic acid-based therapies, microbiome modulation, and phage-based interventions, highlighting their potential against challenging pathogens like HSV-2 and Treponema pallidum. By examining these established and emerging approaches, this review prioritizes critical opportunities for innovation in biologic therapeutics, addressing unmet needs in STI management. It advocates for integrated strategies leveraging antigenic conservation, host immunity modulation, and novel delivery platforms to achieve durable prophylaxis and effective treatment for high-burden infections globally.","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":" ","pages":"e0010724"},"PeriodicalIF":19.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging hybrid shigatoxigenic and enteropathogenic Escherichia coli serotype O80:H2 in humans and calves. 人类和小牛中新出现的致病性和致病性大肠埃希菌O80:H2血清型。

IF 19 1区医学

Clinical Microbiology Reviews Pub Date : 2025-05-29 DOI: 10.1128/cmr.00011-25

Jacques G Mainil, Keiji Nakamura, Rie Ikeda, Florence Crombé, Jacob Diderich, Marc Saulmont, Denis Piérard, Damien Thiry, Tetsuya Hayashi

{"title":"Emerging hybrid shigatoxigenic and enteropathogenic Escherichia coli serotype O80:H2 in humans and calves.","authors":"Jacques G Mainil, Keiji Nakamura, Rie Ikeda, Florence Crombé, Jacob Diderich, Marc Saulmont, Denis Piérard, Damien Thiry, Tetsuya Hayashi","doi":"10.1128/cmr.00011-25","DOIUrl":"https://doi.org/10.1128/cmr.00011-25","url":null,"abstract":"SUMMARYAttaching-effacing (AE) lesion- and Shiga toxin-producing Escherichia (E.) coli (AE-STEC), previously known as \"enterohemorrhagic E. coli\" (EHEC), are responsible for (hemorrhagic) enterocolitis (HC) and hemolytic uremic syndrome (HUS) in humans. The most frequent and pathogenic AE-STEC belong to a few O:H major serotypes that are responsible for the majority of cases and outbreaks worldwide. From time to time, one or another non-major O:H serotype can emerge, causing either local outbreaks or a a progressive increase in clinical cases. One of these minor serotypes is O80:H2, which has been progressively emerging in Western Europe, especially in France, since 2010. AE-STEC O80:H2 are responsible for not only HC and HUS but also invasive infections with bacteremia and internal organ infection. In parallel to their emergence in humans, AE-STEC and enteropathogenic E. coli (EPEC) O80:H2 have also been emerging in young calves suffering diarrhea and enteritis and, more rarely septicemia, in Belgium since 2009. In this manuscript, an overview of AE-STEC and EPEC O80:H2 infections in humans and calves is presented, with particular focus on the clinical manifestations, the prevalence and incidence in Western Europe, and the identification of the potential reservoir(s). In addition, the results of a large-scale whole genome-based phylogenetic analysis of 417 published and unpublished genome sequences currently available in the literature and in the NCBI and EnteroBase databases are presented with hypotheses on the origin and evolution of this new hybrid AE-STEC and EPEC serotype.","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":" ","pages":"e0001125"},"PeriodicalIF":19.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Practical Guidance for Clinical Microbiology Laboratories: Antibody and antigen detection methods for dimorphic fungal infections. 临床微生物实验室实用指南：二形真菌感染的抗体和抗原检测方法。

IF 36.8 1区医学

Clinical Microbiology Reviews Pub Date : 2025-05-21 DOI: 10.1128/cmr.00005-20

Elitza S Theel,Julianne V Kus,Thomas E Grys,Neil M Ampel,Ilan S Schwartz,Sean X Zhang

引用次数: 0

Correction for Moreland et al., "Rapid and accurate testing for urinary tract infection: new clothes for the emperor". 更正Moreland等人的“快速准确的尿路感染检测：皇帝的新衣”。

IF 36.8 1区医学

Clinical Microbiology Reviews Pub Date : 2025-05-14 DOI: 10.1128/cmr.00103-25

Robert B Moreland,Linda Brubaker,Lana Tinawi,Alan J Wolfe

引用次数: 0

Recent advances in therapeutic probiotics: insights from human trials 治疗性益生菌的最新进展：来自人体试验的见解

IF 36.8 1区医学

Clinical Microbiology Reviews Pub Date : 2025-04-22 DOI: 10.1128/cmr.00240-24

Mu-Yeol ChoJe-Hyun EomEun-Mi ChoiSeung-Jo YangDahye LeeYoung Youn KimHye-Sung KimInseong Hwang1Apple Tree Institute of Biomedical Science, Apple Tree Medical Foundation, Goyang-si, South Korea2DOCSmedi, Co., Ltd., Goyang-si, South Korea3Department of Orthodontics, Apple Tree Dental Hospital, Goyang-si, South Korea4Department of Oral and Maxillofacial Surgery, Apple Tree Dental Hospital, Goyang-si, South KoreaChristopher Staley

引用次数: 0

Vaginal mycobiome characteristics and therapeutic strategies in vulvovaginal candidiasis (VVC): differentiating pathogenic species and microecological features for stratified treatment 外阴阴道念珠菌病（VVC）的阴道菌群特征和治疗策略：区分病原种类和微生态特征进行分层治疗

IF 36.8 1区医学

Clinical Microbiology Reviews Pub Date : 2025-04-22 DOI: 10.1128/cmr.00284-24

Zimo LiuHua YangRoujie HuangXiaochuan LiTianshu SunLan Zhu1Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetric & Gynecologic Diseases, State Key Laboratory of Common Mechanism Research for Major Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical Collegehttps://ror.org/02drdmm93, Beijing, China2State Key Laboratory of Complex, Severe, and Rare Diseases, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China3Clinical Biobank, Center for Biomedical Technology, Institute of Clinical Medicine, National Science and Technology Key Infrastructure on Translational Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical Collegehttps://ror.org/02drdmm93, Beijing, ChinaJorge CervantesLina Restrepo

引用次数: 0

Henipaviruses: epidemiology, ecology, disease, and the development of vaccines and therapeutics. 亨尼帕病毒：流行病学，生态学，疾病，以及疫苗和治疗方法的发展。

IF 19 1区医学

Clinical Microbiology Reviews Pub Date : 2025-03-13 Epub Date: 2024-12-23 DOI: 10.1128/cmr.00128-23

Jessica R Spengler, Michael K Lo, Stephen R Welch, Christina F Spiropoulou

引用次数: 0